Vib-ugent Center for Inflammation Research
- 04-03-2025
Nanobodies Targeting the Tumor Microenvironment and Their Formulation as Nanomedicines.
Lorem eiusmod labore dolore consectetur aliqua. labore . sit sit magna elit . dolor incididunt tempor sit et tempor incididunt . do ut eiusmod elit . sit aliqua. do incididunt aliqua. dolor magna .
elit consectetur Lorem amet ut ipsum . magna incididunt amet do dolore elit ut . elit ipsum elit sit incididunt consectetur aliqua. . incididunt dolor dolor dolor dolor dolore . tempor adipiscing amet amet .
Lorem sed elit tempor sed . tempor consectetur incididunt magna . incididunt sed sit amet adipiscing magna do ipsum . tempor sed labore dolor elit ipsum dolore . sed (...)
- 18-03-2010
Impact of Elevation of Total Bilirubin Level and Etiology of the Liver Disease on Serum N-glycosylation Patterns in Mice and Humans
The GlycoFibroTest and GlycoCirrhoTest are noninvasive alternatives for liver biopsy that can be used as a follow-up tool for fibrosis patients and to diagnose cirrhotic patients, respectively. These tests are based on the altered N-glycosylation of total serum protein. Our aim was to investigate the impact of etiology on the alteration of N-glycosylation and whether other characteristics of liver patients could have an influence on N-glycosylation. In human liver patients, no specific alteration could be found to make a distinction according to etiological factor, although alcoholic patients had a significant higher mean value for the GlycoCirrhoTest. Undergalactosylation did (...)
Erc-funded Postdoctoral Position Focusing on Nanobody Development for Therapeutic Brain Delivery
VIB categories: {acf_job_categories}
TCP domains: {acf_job_domain}Lab Technician to Support Irc Cell Core Facility
VIB categories: {acf_job_categories}
TCP domains: {acf_job_domain}
Immunotherapy & Tumor Biology
Harness the immune system’s power to specifically target and eliminate cancer cells.
- active
Exevir Bio
ExeVir’s platform isolates and optimizes single-domain antibodies from immunized llamas, yielding candidates with exceptional neutralization breadth and manufacturability.
Its lead nanobody constructs have shown preclinical efficacy against SARS-CoV-2 variants and other respiratory viruses, positioning ExeVir as a rapid-response antiviral innovator.
Backed by V-Bio Ventures, UCB Ventures, and EU grants, ExeVir is scaling manufacturing and advancing first-in-human studies.
